Mogamulizumab, sold under the brand name Poteligeo, is a humanized, afucosylated monoclonal antibody targeting CC chemokine receptor type 4. It is given by injection into a vein. From Wikipedia
The agreement with Canada’s federal government will fund new treatments, diagnostics, and screening for rare diseases over three years.
